Halozyme Therapeutics, Inc.
HALO
4
|
$38.315
-2.06%
33K
|
Health Technology
(0.0% 1d) (-2.4% 1m) (19.1% 1y) (0.0% 2d) (0.4% 3d) (1.2% 7d) (11.21% volume)
Earnings Calendar: 2024-02-20
Market Cap: $ 4,868,083,206
http://www.halozyme.com
Sec Filling | Patents | 132 employees
(US) Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
add to watch list Paper trade email alert is off
Press-releases
Halozyme to Report First Quarter 2024 Financial and Operating Results
Published: 2024-04-23 (Crawled : 13:30) - biospace.com/
HALO 4 | $38.315 -2.06% 33K
|
Health Technology
|
| O: 0.1%
H: 1.73%
C: 0.57%
first report financial results
Halozyme to Participate in Upcoming Investor Conferences
Published: 2024-02-27 (Crawled : 13:30) - prnewswire.com
HALO 4 | $38.315 -2.06% 33K
|
Health Technology
|
| O: 0.55%
H: 1.5%
C: -0.13%
Halozyme to Participate in Upcoming Investor Conferences - February 27, 2024
Published: 2024-02-27 (Crawled : 14:00) - biospace.com/
HALO 4 | $38.315 -2.06% 33K
|
Health Technology
|
| O: 0.55%
H: 1.5%
C: -0.13%
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
Published: 2024-02-20 (Crawled : 21:00) - prnewswire.com
HALO 4 | $38.315 -2.06% 33K
|
Health Technology
|
| O: 4.78%
H: 7.0%
C: 1.7%
year financial results
Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results
Published: 2024-02-08 (Crawled : 22:00) - prnewswire.com
HALO 4 | $38.315 -2.06% 33K
|
Health Technology
|
| O: 0.4%
H: 0.69%
C: 0.31%
report year financial results
Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis
Published: 2024-01-18 (Crawled : 13:30) - prnewswire.com
HALO 4 | $38.315 -2.06% 33K
|
Health Technology
|
| O: 0.58%
H: 0.63%
C: -3.64%
vyvdura japan approval
Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types
Published: 2024-01-16 (Crawled : 09:00) - biospace.com/
HALO 4 | $38.315 -2.06% 33K
|
Health Technology
|
| O: -0.78%
H: 6.95%
C: 6.44%
tecentriq first approval cancer immunotherapy roche
Halozyme to Host Investor Business Forum and Long-Term Outlook Call
Published: 2024-01-12 (Crawled : 14:30) - prnewswire.com
HALO 4 | $38.315 -2.06% 33K
|
Health Technology
|
| O: 1.7%
H: 1.43%
C: -0.52%
business
Halozyme to Present at Upcoming Investor Conferences - November 27, 2023
Published: 2023-11-27 (Crawled : 14:30) - biospace.com/
HALO 4 | $38.315 -2.06% 33K
|
Health Technology
|
| O: -0.72%
H: 2.49%
C: 1.92%
Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.
Published: 2023-11-17 (Crawled : 16:00) - biospace.com/
TEVA | $13.06 0.38% 1.4M
|
Health Technology
|
| O: 0.91%
H: 2.6%
C: 2.38%
HALO 4 | $38.315 -2.06% 33K
|
Health Technology
|
| O: 0.94%
H: 1.8%
C: 0.1%
forteo approval teva
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 45% | 55% |
Top 10 Gainers
SGBX | $0.26 80.43% 54M
|
Producer Manufacturing
LICN | $1.0 78.57% 3.3M
|
CSSE 4 | $0.2656 74.39% 9.7M
|
Consumer Services
BRFH 4 | $1.89 71.82% 32M
|
Manufacturing
ACON | $0.49 70.14% 24M
|
n/a
BOF | $1.95 66.67% 920K
|
MTC | $3.62 61.61% 790K
|
Technology Services
AMST | $3.22 61.0% 720K
|
Technology Services
PCSA | $2.28 40.74% 37M
|
Producer Manufacturing
EVA | $0.626 39.14% 2.3M
|
Process Industries
Last 48 Hours Insiders Buying
MNSB P 1470 | $15.38 -3.21% 3.9K
|
Finance
|
12:00
RKT P 347 | $11.815 -5.86% 270K
|
Finance
|
22:30
NWFL | News | $24.21 55
|
Finance
|
22:00
TGEN P 10000 | $0.68 20K
|
Utilities
|
20:01
RMCF | $3.51 -1.13% 20
|
Consumer Non-Durables
|
20:10